What is Sézary syndrome?
Sézary syndrome is a rare type of cutaneous T-cell lymphoma (CTCL), a cancer of white blood cells called T lymphocytes. The cancer cells, known as Sézary cells, are found in the skin, the lymph nodes and the blood at the same time.
Doctors recognise it by three main features:
- erythroderma: red, inflamed skin covering most of the body
- swollen lymph nodes
- cancerous T cells in the blood
Sézary syndrome is the leukaemic form of CTCL. It is related to mycosis fungoides, the most common skin lymphoma, but behaves more aggressively. It usually needs whole-body (systemic) treatment rather than skin treatment alone.
There is no simple cure for most people. However, modern treatments can control the disease and relieve the intense itch, often for years. A stem cell transplant from a donor offers the chance of long-term remission for some fit patients.
1. Key facts at a glance
| Feature | Details |
|---|---|
| How common | Very rare; fewer than 5% of cutaneous T-cell lymphomas |
| Typical age | Usually over 60 |
| Sex | More common in men |
| Cell of origin | Mature CD4-positive “helper” T cells, thought to come from central memory T cells that circulate between blood, skin and lymph nodes |
| Main symptom | Severe, persistent itching |
| Stage at diagnosis | Always classed as advanced (stage IV) because the blood is involved |
| Main treatments | Extracorporeal photopheresis, mogamulizumab, bexarotene, interferon, low-dose methotrexate, skin treatments; donor stem cell transplant for selected patients |
| Outlook | Median survival roughly 2-5 years, with wide variation; some people live much longer |
2. Causes and risk factors
The cause of Sézary syndrome is not known. It is not infectious and is not inherited.
The cancer cells carry many acquired changes in their DNA. These often affect genes that control T-cell signalling (such as PLCG1 and CARD11), cell growth (such as TP53 and CDKN2A) and the way DNA is packaged. Many cells show losses and gains of whole chromosome segments.
Ongoing irritation of the immune system, for example by Staphylococcus aureus bacteria on damaged skin, may help drive the disease, but this has not been proven to cause it.
| Factor | Notes |
|---|---|
| Age | Risk rises with age |
| Male sex | Men are affected more often than women |
| Previous mycosis fungoides | A small number of people with mycosis fungoides develop blood involvement. When this happens, it is usually called “Sézary syndrome secondary to mycosis fungoides” or erythrodermic mycosis fungoides with blood involvement |
3. How does it look?
3.1 The skin
| Feature | What it looks like |
|---|---|
| Erythroderma | Bright red or purple-red skin over 80% or more of the body, often thickened and warm to the touch |
| Scaling | Fine or coarse flakes of skin shed constantly; bedding and clothes are often covered in scales |
| Thickened palms and soles | Yellowish, hardened skin (keratoderma) with deep, painful cracks |
| Face | Swelling and thickening of the facial skin, sometimes giving a “lion-like” (leonine) look; redness around the eyes |
| Eyelids | Outward turning of the lower lids (ectropion), causing watery, sore eyes |
| Hair | Thinning of scalp hair and loss of eyebrows and body hair |
| Nails | Thick, ridged, brittle or misshapen nails |
| Plaques or tumours | Raised, firm areas may appear on top of the red skin, especially if the disease progresses |
| Scratch marks | Broken skin and crusts from constant scratching, often infected |
3.2 Lymph nodes
Lymph nodes in the neck, armpits and groin are often enlarged. They are usually painless, firm and mobile.
3.3 Under the microscope
| Test | Typical finding |
|---|---|
| Blood film | Sézary cells: T cells with a folded, brain-like (cerebriform) nucleus |
| Flow cytometry of blood | A raised number of CD4-positive T cells that have lost CD7 and/or CD26, often a CD4:CD8 ratio of 10 or more |
| T-cell receptor gene test | The same T-cell clone in the blood (and ideally the skin or nodes) |
| Skin biopsy | Atypical T cells in the upper skin. Changes can be subtle, and up to a third of biopsies look non-specific, like eczema |
| Lymph node biopsy | Ranges from reactive changes to complete replacement by lymphoma |
4. Symptoms
Symptoms can be severe and affect daily life, sleep and mood.
| Symptom | What people experience |
|---|---|
| Itching (pruritus) | Present in almost everyone; often intense and constant, worse at night and not relieved by usual antihistamines |
| Burning and tight skin | Skin feels raw, tight or painful; cracks on hands and feet hurt with walking or gripping |
| Feeling cold or shivering | The red skin loses heat easily, so people often feel cold even in warm rooms |
| Shedding skin | Large amounts of flaking skin every day |
| Tiredness | Often marked, from poor sleep, inflammation and anaemia |
| Fever, sweats and weight loss | Can occur, especially with advanced disease or infection |
| Swollen glands | Lumps in the neck, armpits or groin |
| Sore, watery eyes | From ectropion and dry eyes |
| Skin infections | Weeping, crusted or painful areas; infection with Staphylococcus aureus or herpes viruses |
| Low mood and anxiety | Common, because of itch, visible skin changes and sleep loss |
4.1 When to get urgent help
Seek medical care quickly if you have:
- a fever, shivering or feeling very unwell, which can be a sign of serious infection (sepsis)
- skin that becomes hot, swollen, painful or weeps pus
- a painful blistering rash, which may be shingles or herpes
- new rapidly growing lumps
Infection is the most common cause of death in Sézary syndrome, so early treatment matters.
5. Diagnosis
Sézary syndrome can be hard to diagnose because it looks like other causes of red skin, such as severe eczema, psoriasis or a drug reaction. It may take several biopsies and blood tests to confirm.
5.1 Diagnostic criteria
Under the ISCL/EORTC criteria, Sézary syndrome needs:
| Requirement | Details |
|---|---|
| Erythroderma | Red skin over at least 80% of the body surface |
| Blood involvement (B2) | At least 1,000 Sézary cells per microlitre of blood, or a large expanded population of abnormal CD4 T cells on flow cytometry (for example CD4:CD8 ratio of 10 or more, or many CD4 cells lacking CD7 or CD26) |
| Clonality | The same T-cell clone in the blood, ideally matching the skin |
5.2 Tests used
| Test | Purpose |
|---|---|
| Skin biopsies | Often several, from different areas |
| Blood flow cytometry | Counts and characterises the abnormal T cells |
| T-cell receptor clonality test | Confirms that the cells come from a single clone |
| Blood tests | Full blood count, lactate dehydrogenase (LDH), kidney and liver function |
| CT or PET-CT scan | Looks for enlarged lymph nodes and organ involvement |
| Lymph node biopsy | If nodes are enlarged, to check how much lymphoma they contain |
| Bone marrow biopsy | Only if needed |
5.3 Staging
Because blood involvement is high (B2), Sézary syndrome is always stage IV:
| Stage | Meaning |
|---|---|
| IVA1 | Erythroderma with heavy blood involvement; lymph nodes not replaced by lymphoma |
| IVA2 | Lymph nodes extensively involved by lymphoma |
| IVB | Spread to internal organs, such as the liver, lungs or bone marrow |
6. Treatment
Treatment is planned by a specialist cutaneous lymphoma team. The aims are to control the disease in the blood, skin and nodes, relieve itching, prevent infection and keep quality of life as good as possible. The 2023 EORTC recommendations are widely used in Europe.
6.1 First-line options
| Treatment | How it works | Key points |
|---|---|---|
| Extracorporeal photopheresis (ECP) | Blood is taken out, white cells are treated with a light-sensitising drug and UVA light, then returned | Well tolerated; often combined with interferon or bexarotene |
| Low-dose methotrexate | Weekly tablets or injections that dampen the abnormal T cells | Inexpensive; blood and liver checks needed |
| Bexarotene | A retinoid tablet | Raises blood fats and lowers thyroid hormone; needs regular blood tests |
| Interferon alpha | Injections that boost the immune response | Flu-like symptoms and tiredness are common |
| Skin-directed treatments | Strong steroid creams, UV light (PUVA) | Relieve symptoms; usually combined with systemic treatment |
6.2 Second-line and later options
| Treatment | Key points |
|---|---|
| Mogamulizumab | Antibody against CCR4, a protein found on Sézary cells. In the MAVORIC trial it doubled progression-free survival compared with vorinostat, with blood responses in about two-thirds of people with Sézary syndrome. A rash, which can mimic the disease, is a common side effect |
| Low-dose alemtuzumab | Antibody against CD52; very effective at clearing blood disease but raises the risk of infection |
| Brentuximab vedotin | For disease in which the cells carry CD30 |
| HDAC inhibitors (romidepsin, vorinostat) | Approved in some countries, including the United States |
| Chemotherapy | Gemcitabine, liposomal doxorubicin or others, mainly for rapidly progressive disease |
| Total skin electron beam therapy | Radiotherapy to the whole skin surface; can quickly improve skin disease, often before transplant |
6.3 Allogeneic stem cell transplant
A donor stem cell transplant is the only treatment that can lead to long-lasting remission in some patients. It is considered for fitter people, usually under about 70, whose disease responds well to earlier treatment. Risks include serious infection and graft-versus-host disease, so careful selection is essential.
6.4 Supportive care
| Problem | Help available |
|---|---|
| Itch | Moisturisers and emollients applied often, bath oils, steroid creams, and medicines such as gabapentin, pregabalin, mirtazapine or aprepitant |
| Infection | Antiseptic washes or bleach baths, prompt antibiotics, and antiviral treatment when needed |
| Feeling cold | Warm clothing and rooms, warm (not hot) showers |
| Eye problems | Lubricating eye drops and eye specialist review for ectropion |
| Nutrition | High-protein diet; the constant shedding of skin uses protein and energy |
| Mental health | Counselling, support groups and treatment for depression or anxiety |
7. Outlook (prognosis)
The outlook varies widely. Median survival is often quoted as about 2-5 years, but some people live for 10 years or more.
| Factor | Effect on outlook |
|---|---|
| Older age | Worse |
| High LDH | Worse |
| Large-cell transformation (lymphoma cells become larger and faster-growing) | Worse |
| Extensive lymph node or organ involvement (stage IVA2 or IVB) | Worse |
| Good response to treatment, especially clearing of blood disease | Better |
| Successful donor stem cell transplant | Can give long-term remission |
8. Follow-up
| What | How often |
|---|---|
| Clinic review and skin check | Every 1-3 months during active treatment |
| Blood flow cytometry | Regularly, to measure blood disease |
| Blood tests for treatment side effects | Depends on the treatment (for example lipids and thyroid on bexarotene) |
| Scans | If symptoms change or to assess response |
9. Frequently asked questions
| Question | Answer |
|---|---|
| Is Sézary syndrome a skin disease or a blood cancer? | It is both: a lymphoma that affects the skin, the blood and the lymph nodes |
| Is it the same as mycosis fungoides? | They are related cutaneous T-cell lymphomas. Sézary syndrome involves the blood from the start and is more aggressive |
| Is it contagious? | No. It cannot be passed to other people, even though the skin can look inflamed |
| Can it be cured? | Most treatments control rather than cure it. A donor stem cell transplant can lead to long-term remission in selected patients |
| Why is the itch so hard to treat? | It is caused by chemicals released by the lymphoma cells and nerve changes in the skin, not by histamine alone |
| Can I use normal moisturisers? | Yes. Plain, fragrance-free emollients used several times a day are one of the most helpful measures |
Resources
- Willemze, R. et al. (2019) ‘The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas’, Blood, 133(16), pp. 1703-1714.
- Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720-1748.
- Campo, E. et al. (2022) ‘The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee’, Blood, 140(11), pp. 1229-1253.
- Olsen, E. et al. (2007) ‘Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)’, Blood, 110(6), pp. 1713-1722.
- Latzka, J. et al. (2023) ‘EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome – Update 2023’, European Journal of Cancer, 195, 113343.
- Hristov, A.C., Tejasvi, T. and Wilcox, R.A. (2021) ‘Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management’, American Journal of Hematology, 96(10), pp. 1313-1328.
- Kim, Y.H. et al. (2018) ‘Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial’, The Lancet Oncology, 19(9), pp. 1192-1204.
- Agar, N.S. et al. (2010) ‘Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal’, Journal of Clinical Oncology, 28(31), pp. 4730-4739.
- Scarisbrick, J.J. et al. (2015) ‘Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model’, Journal of Clinical Oncology, 33(32), pp. 3766-3773.
- de Masson, A. et al. (2014) ‘Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas’, Haematologica, 99(3), pp. 527-534.
- National Cancer Institute (2026) Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ) – Patient Version. Available at: https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.